Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists

British Journal of Pharmacology

Volumn 171, Issue 16, 2014, Pages 3777-3800

  Schroder W ^a   Lambert, D G ^b   Ko, M C ^c   Koch, T ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL N TYPE; LIGAND; MU OPIATE RECEPTOR; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; OPIATE RECEPTOR; ANALGESIC AGENT; ISOPROTEIN;

ANALGESIA; ANTIHYPERSENSITIVE EFFECT; ANTINOCICEPTION; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DESENSITIZATION; DIMERIZATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; EVOKED RESPONSE; HUMAN; INFLAMMATORY PAIN; INTERNALIZATION; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PERIPHERAL NERVOUS SYSTEM; PRIMATE; PRIORITY JOURNAL; PRONOCICEPTIVE EFFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; SEDATION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CHEMISTRY; METABOLISM;

ANALGESICS; ANIMALS; CALCIUM CHANNELS, N-TYPE; HUMANS; PAIN; PROTEIN ISOFORMS; RECEPTORS, OPIOID;

EID: 84901225366     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12744     Document Type: Review

References (268)

1. 2+ channel current in rat sensory neurons by a G-protein-independent mechanism. J Neurosci 17: 8721-8728.
2. Abdulla FA, Smith PA, (1998). Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci 18: 9685-9694.
3. Agostini S, Eutamene H, Broccardo M, Improta G, Petrella C, Theodorou V, et-al. (2009). Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain 141: 292-299.
4. Albrecht D, Bluhdorn R, Siegmund H, Berger H, Calo' G, (2001). Inhibitory action of nociceptin/orphanin FQ on functionally different thalamic neurons in urethane-anaesthetized rats. Br J Pharmacol 134: 333-342.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
7. Altier C, Khosravani H, Evans RM, Hameed S, Peloquin JB, Vartian BA, et-al. (2006). ORL1 receptor-mediated internalization of N-type calcium channels. Nat Neurosci 9: 31-40.
8. Andoh T, Itoh M, Kuraishi Y, (1997). Nociceptin gene expression in rat dorsal root ganglia induced by peripheral inflammation. Neuroreport 8: 2793-2796.
9. Andrade A, Denome S, Jiang YQ, Marangoudakis S, Lipscombe D, (2010). Opioid inhibition of N-type Ca2+ channels and spinal analgesia couple to alternative splicing. Nat Neurosci 13: 1249-1256.
10. Anton B, Fein J, To T, Li X, Silberstein L, Evans CJ, (1996). Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol 368: 229-251.
11. Baiula M, Bedini A, Carbonari G, (2013). Molecular mechanisms mediating nociceptin/orphanin FQ receptor signaling, desensitization and internalization. Curr Mol Pharmacol 5: 372-381.
12. Bee LA, Dickenson AH, (2008). Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain 140: 209-223.
13. Bee LA, Bannister K, Rahman W, Dickenson AH, (2011). Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 152: 131-139.
14. Beedle AM, McRory JE, Poirot O, Doering CJ, Altier C, Barrere C, et-al. (2004). Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 7: 118-125.
15. Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D, (2004). Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 41: 127-138.
16. 3H]-nociceptin ligand-binding and nociceptin opioid receptor mRNA expression in the human brain. Neuroscience 121: 629-640.
17. Bertorelli R, Corradini L, Rafiq K, Tupper J, Calo G, Ongini E, (1999). Nociceptin and the ORL-1 ligand [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol 128: 1252-1258.
18. Bohn LM, Gainetdinov RR, Caron MG, (2004). G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. Neuromolecular Med 5: 41-50.
19. Bridge KE, Wainwright A, Reilly K, Oliver KR, (2003). Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 118: 513-523.
20. Briscini L, Corradini L, Ongini E, Bertorelli R, (2002). Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur J Pharmacol 447: 59-65.
21. Brookes ZL, Stedman EN, Guerrini R, Lawton BK, Calo G, Lambert DG, (2007). Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol Heart Circ Physiol 293: H2977-H2985.
22. Brookes ZL, Stedman EN, Brown NJ, Hebbes CP, Guerrini R, Calo G, et-al. (2013). The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo. PLoS ONE 8: e74943.
23. Bruchas MR, Macey TA, Lowe JD, Chavkin C, (2006). Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281: 18081-18089.
24. Bryant W, Janik J, Baumann M, Callahan P, (1998). Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. Brain Res 807: 228-233.
25. Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M, et-al. (1994). Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett 347: 284-288.
26. Byford AJ, Anderson A, Jones PS, Palin R, Houghton AK, (2007). The hypnotic, electroencephalographic, and antinociceptive properties of nonpeptide ORL1 receptor agonists after intravenous injection in rodents. Anesth Analg 104: 174-179.
27. Calo G, Guerrini R, (2013). Medicinal chemistry, pharmacology, and biological actions of peptide ligands selective for the nociceptin/orphanin FQ receptor. In:, Ko MC, (ed.). Research and Development of Opioid-Related Ligands. American Chemical Society: Washington, DC, pp. 275-325.
28. Calo G, Rizzi A, Marzola G, Guerrini R, Salvadori S, Beani L, et-al. (1998). Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br J Pharmacol 125: 373-378.
29. Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D, (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129: 1261-1283.
30. Carpenter KJ, Vithlani M, Dickenson AH, (2000). Unaltered peripheral excitatory actions of nociceptin contrast with enhanced spinal inhibitory effects after carrageenan inflammation: an electrophysiological study in the rat. Pain 85: 433-441.
31. Chan AS, Wong YH, (2000). Regulation of c-Jun N-terminal kinase by the ORL(1) receptor through multiple G proteins. J Pharmacol Exp Ther 295: 1094-1100.
32. Chan JS, Yung LY, Lee JW, Wu YL, Pei G, Wong YH, (1998). Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins. J Neurochem 71: 2203-2210.
33. Chang C, Byon W, Lu Y, Jacobsen LK, Badura LL, Sawant-Basak A, et-al. (2011). Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J 13: 565-575.
34. Chen X, Geller EB, Adler MW, (2007). Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test. Eur J Pharmacol 557: 32-36.
35. Chen Y, Sommer C, (2006). Nociceptin and its receptor in rat dorsal root ganglion neurons in neuropathic and inflammatory pain models: implications on pain processing. J Peripher Nerv Syst 11: 232-240.
36. Chen Y, Sommer C, (2007). Activation of the nociceptin opioid system in rat sensory neurons produces antinociceptive effects in inflammatory pain: involvement of inflammatory mediators. J Neurosci Res 85: 1478-1488.
37. Chen YL, Li AH, Yeh TH, Chou AH, Wang HL, (2009). Nocistatin and nociceptin exert opposite effects on the excitability of central amygdala nucleus-periaqueductal gray projection neurons. Mol Cell Neurosci 40: 76-88.
38. Chesterfield M, Janik J, Murphree E, Lynn C, Schmidt E, Callahan P, (2006). Orphanin FQ/nociceptin is a physiological regulator of prolactin secretion in female rats. Endocrinology 147: 5087-5093.
39. Chieng B, Christie MJ, (2010). Somatostatin and nociceptin inhibit neurons in the central nucleus of amygdala that project to the periaqueductal grey. Neuropharmacology 59: 425-430.
40. Christoph T, Koch T, Tzschentke TM, Kögel B, Schiene K, (2013). Interactions of opioid and nociceptin/orphaninFQ (NOP) receptors in acute nociception and diabetic heat hyperalgesia as revealed in opioid/NOP receptor knockout mice. In: EFIC-8th 'Pain in Europe' Congress; 9-12 October 2013; Florence, Italy. 2013. p. Abs 600.
41. Ciccocioppo R, Angeletti S, Sanna PP, Weiss F, Massi M, (2000). Effect of nociceptin/orphanin FQ on the rewarding properties of morphine. Eur J Pharmacol 404: 153-159.
42. Civelli O, (2008). The orphanin FQ/nociceptin (OFQ/N) system. Results Probl Cell Differ 46: 1-25.
43. Connor M, Christie MJ, (1998). Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol 509: 47-58.
44. Connor M, Vaughan CW, Chieng B, Christie MJ, (1996a). Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol 119: 1614-1618.
45. Connor M, Yeo A, Henderson G, (1996b). The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol 118: 205-207.
46. Corbani M, Gonindard C, Meunier JC, (2004). Ligand-regulated internalization of the opioid receptor-like 1: a confocal study. Endocrinology 145: 2876-2885.
47. Corboz MR, Rivelli MA, Egan RW, Tulshian D, Matasi J, Fawzi AB, et-al. (2000). Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung. Eur J Pharmacol 402: 171-179.
48. Corboz MR, Fernandez X, Egan RW, Hey JA, (2001). Inhibitory activity of nociceptin/orphanin FQ on capsaicin-induced bronchoconstriction in the guinea-pig. Life Sci 69: 1203-1211.
49. Corradini L, Briscini L, Ongini E, Bertorelli R, (2001). The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res 905: 127-133.
50. Courteix C, Coudore-Civiale MA, Privat AM, Pelissier T, Eschalier A, Fialip J, (2004). Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain. Pain 110: 236-245.
51. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR, (2014). Challenges for opioid receptor nomenclature. Br J Pharmacol. doi: 10.1111/bph.12612; [Epub: 15/2/2014].
52. Cremeans CM, Gruley E, Kyle DJ, Ko MC, (2012). Roles of mu-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J Pharmacol Exp Ther 343: 72-81.
53. Curro D, Yoo JH, Anderson M, Song I, Del Valle J, Owyang C, (2001). Molecular cloning of the orphanin FQ receptor gene and differential tissue expression of splice variants in rat. Gene 266: 139-145.
54. Dautzenberg FM, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, et-al. (2001). Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 298: 812-819.
55. Depner UB, Reinscheid RK, Takeshima H, Brune K, Zeilhofer HU, (2003). Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor. Eur J Neurosci 17: 2381-2387.
56. Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM, (2011). Orphanin FQ/nociceptin activates nuclear factor kappa B. J Neuroimmune Pharmacol 6: 617-625.
57. Dumont M, Lemaire S, (1998). Characterization of the high affinity [3H]nociceptin binding site in membrane preparations of rat heart: correlations with the non-opioid dynorphin binding site. J Mol Cell Cardiol 30: 2751-2760.
58. Erb K, Liebel JT, Tegeder I, Zeilhofer HU, Brune K, Geisslinger G, (1997). Spinally delivered nociceptin/orphanin FQ reduces flinching behaviour in the rat formalin test. Neuroreport 8: 1967-1970.
59. Evans RM, You H, Hameed S, Altier C, Mezghrani A, Bourinet E, et-al. (2010). Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem 285: 1032-1040.
60. Faber ES, Chambers JP, Evans RH, Henderson G, (1996). Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br J Pharmacol 119: 189-190.
61. Fields H, (2004). State-dependent opioid control of pain. Nat Rev Neurosci 5: 565-575.
62. Florin S, Suaudeau C, Meunier JC, Costentin J, (1996). Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol 317: 9-13.
63. Florin S, Suaudeau C, Meunier JC, Costentin J, (1997). Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice. Neuroreport 8: 705-707.
64. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H, Iwabe N, et-al. (1994). cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett 343: 42-46.
65. Fukuda K, Shoda T, Morikawa H, Kato S, Mori K, (1997). Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett 412: 290-294.
66. 2 by the nociceptin receptor expressed in Chinese hamster ovary cells. J Neurochem 71: 2186-2192.
67. Gavioli EC, Rizzi A, Marzola G, Zucchini S, Regoli D, Calo' G, (2007). Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. Peptides 28: 1229-1239.
68. Giuliani S, Tramontana M, Lecci A, Maggi CA, (1997). Effect of nociceptin on heart rate and blood pressure in anaesthetized rats. Eur J Pharmacol 333: 177-179.
69. Giuliani S, Lecci A, Maggi CA, (2000). Nociceptin and neurotransmitter release in the periphery. Peptides 21: 977-984.
70. Goeldner C, Spooren W, Wichmann J, Prinssen EP, (2012). Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair. Psychopharmacology (Berl) 222: 203-214.
71. Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, et-al. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485: 400-404.
72. Graversen C, Olesen SS, Olesen AE, Steimle K, Farina D, Wilder-Smith OH, et-al. (2012). The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. Br J Clin Pharmacol 73: 363-372.
73. Grisel JE, Mogil JS, (2000). Effects of supraspinal orphanin FQ/nociceptin. Peptides 21: 1037-1045.
74. Halford WP, Gebhardt BM, Carr DJ, (1995). Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J Neuroimmunol 59: 91-101.
75. Hao JX, Xu IS, Wiesenfeld-Hallin Z, Xu XJ, (1998). Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain 76: 385-393.
76. Hao S, Ogawa H, (1998). Naltrexone, but not atropine or yohimbine, antagonizes suppression of formalin-induced spinal sensitization by intrathecal nociceptin. Life Sci 63: PL163-PL173.
77. Hawes BE, Fried S, Yao X, Weig B, Graziano MP, (1998). Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization. J Neurochem 71: 1024-1033.
78. Hayashi S, Hirao A, Nakamura H, Yamamura K, Mizuno K, Yamashita H, (2009). Discovery of 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3- piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable and potential-risk reduced novel non-peptide nociceptin/orphanin FQ receptor agonist as antianxiety drug. Chem Biol Drug Des 74: 369-381.
79. Heinricher MM, Morgan MM, Tortorici V, Fields HL, (1994). Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience 63: 279-288.
80. Heinricher MM, McGaraughty S, Grandy DK, (1997). Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 78: 3351-3358.
81. Heinricher MM, McGaraughty S, Tortorici V, (2001). Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 85: 280-286.
82. Helyes Z, Nemeth J, Pinter E, Szolcsanyi J, (1997). Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 121: 613-615.
83. Higgins GA, Grottick AJ, Ballard TM, Richards JG, Messer J, Takeshima H, et-al. (2001). Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology 41: 97-107.
84. Hiramatsu M, Miwa M, Hashimoto K, Kawai S, Nomura N, (2008). Nociceptin/orphanin FQ reverses mecamylamine-induced learning and memory impairment as well as decrease in hippocampal acetylcholine release in the rat. Brain Res 1195: 96-103.
85. Homma E, Collins JG, Kitahata LM, Matsumoto M, Kawahara M, (1983). Suppression of noxiously evoked WDR dorsal horn neuronal activity by spinally administered morphine. Anesthesiology 58: 232-236.
86. Hostetler ED, Sanabria-Bohorquez S, Eng W, Joshi AD, Patel S, Gibson RE, et-al. (2013). Evaluation of [(1)(8)F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human. Neuroimage 68: 1-10.
87. Hu E, Calo G, Guerrini R, Ko MC, (2010). Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain 148: 107-113.
88. Hygate DA, Wong WJ, Manguiat R, Collins D, Jani M, Wilson A, et-al. (2012a). Evaluation of pregabalin analgesic effects in a non-human primate (NHP) model of neuropathic pain induced by L7 spinal nerve ligation (SNL). In: 14th World Congress on Pain; 27-31 August 2012; Milano, Italy. 2012. p. Abs PF261.
89. Hygate DA, Wong WJ, Manguiat R, Collins D, Jani M, Wilson A, et-al. (2012b). Validation of a non-human primate (NHP) model of neuropathic pain induced by spinal nerve ligation (SNL). In: 14th World Congress on Pain; 27-31 August 2012; Milano, Italy. 2012. p. Abs PF260.
90. Inoue M, Shimohira I, Yoshida A, Zimmer A, Takeshima H, Sakurada T, et-al. (1999). Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. J Pharmacol Exp Ther 291: 308-313.
91. Itoh M, Takasaki I, Andoh T, Nojima H, Tominaga M, Kuraishi Y, (2001). Induction by carrageenan inflammation of prepronociceptin mRNA in VR1-immunoreactive neurons in rat dorsal root ganglia. Neurosci Res 40: 227-233.
92. Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ Jr, et-al. (1997). Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A 94: 14854-14858.
93. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, et-al. (2000). A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97: 4938-4943.
94. Jhamandas KH, Sutak M, Henderson G, (1998). Antinociceptive and morphine modulatory actions of spinal orphanin FQ. Can J Physiol Pharmacol 76: 314-324.
95. Jia Y, Linden DR, Serie JR, Seybold VS, (1998). Nociceptin/orphanin FQ binding increases in superficial laminae of the rat spinal cord during persistent peripheral inflammation. Neurosci Lett 250: 21-24.
96. Johnson EE, Connor M, (2007). Towards a receptor for nocistatin? Br J Pharmacol 152: 415-416.
97. Ju J, Shin DJ, Na YC, Yoon MH, (2013). Role of spinal opioid receptor on the antiallodynic effect of intrathecal nociceptin in neuropathic rat. Neurosci Lett 542: 118-122.
98. Kamei J, Ohsawa M, Kashiwazaki T, Nagase H, (1999). Antinociceptive effects of the ORL1 receptor agonist nociceptin/orphanin FQ in diabetic mice. Eur J Pharmacol 370: 109-116.
99. Kapusta DR, Sezen SF, Chang JK, Lippton H, Kenigs VA, (1997). Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci 60: L15-L21.
100. Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, et-al. (2007). SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 320: 934-943.
101. Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, et-al. (2011). Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/mu receptor agonists in the sciatic nerve ligation chronic pain model in mice. J Pharmacol Exp Ther 339: 687-693.
102. Kimura Y, Fujita M, Hong J, Lohith TG, Gladding RL, Zoghbi SS, et-al. (2011). Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. J Nucl Med 52: 1638-1645.
103. King M, Chang A, Pasternak GW, (1998). Functional blockade of opioid analgesia by orphanin FQ/nociceptin. Biochem Pharmacol 55: 1537-1540.
104. King MA, Rossi GC, Chang AH, Williams L, Pasternak GW, (1997). Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. Neurosci Lett 223: 113-116.
105. Kissin I, (2010). The development of new analgesics over the past 50-years: a lack of real breakthrough drugs. Anesth Analg 110: 780-789.
106. Klukovits A, Tekes K, Gunduz CO, Benyhe S, Borsodi A, Deak BH, et-al. (2010). Nociceptin inhibits uterine contractions in term-pregnant rats by signaling through multiple pathways. Biol Reprod 83: 36-41.
107. Knoflach F, Reinscheid RK, Civelli O, Kemp JA, (1996). Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci 16: 6657-6664.
108. Ko MC, (2004). Antinociceptive effects of ORL1 agonists in monkeys. FASEB J 18: A961.
109. Ko MC, Naughton NN, (2009). Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain 10: 509-516.
110. Ko MC, Naughton NN, Traynor JR, Song MS, Woods JH, Rice KC, et-al. (2002). Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 135: 943-950.
111. Ko MC, Wei H, Woods JH, Kennedy RT, (2006). Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther 318: 1257-1264.
112. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP, (2009). Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34: 2088-2096.
113. Kohno T, Ji RR, Ito N, Allchorne AJ, Befort K, Karchewski LA, et-al. (2005). Peripheral axonal injury results in reduced mu opioid receptor pre- and post-synaptic action in the spinal cord. Pain 117: 77-87.
114. Kolesnikov YA, Pasternak GW, (1999). Peripheral orphanin FQ/nociceptin analgesia in the mouse. Life Sci 64: 2021-2028.
115. Kotlinska J, Wichmann J, Rafalski P, Talarek S, Dylag T, Silberring J, (2003). Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence. Neuroreport 14: 601-604.
116. Kummer W, Fischer A, (1997). Nociceptin and its receptor in guinea-pig sympathetic ganglia. Neurosci Lett 234: 35-38.
117. Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D, (2012). Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig 32 (Suppl. 1): 53-63.
118. Lai CC, Wu SY, Dun SL, Dun NJ, (1997). Nociceptin-like immunoreactivity in the rat dorsal horn and inhibition of substantia gelatinosa neurons. Neuroscience 81: 887-891.
119. Lambert DG, (2008). The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7: 694-710.
120. Lazzeri M, Calo G, Spinelli M, Guerrini R, Beneforti P, Sandri S, et-al. (2001). Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 166: 2237-2240.
121. Lazzeri M, Calo G, Spinelli M, Malaguti S, Guerrini R, Salvadori S, et-al. (2006). Daily intravesical instillation of 1-mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 176: 2098-2102.
122. (3)H]nociceptin binding sites on medullar primary afferent fibers. J Neurosci Res 68: 496-500.
123. Lecci A, Giuliani S, Meini S, Maggi CA, (2000). Nociceptin and the micturition reflex. Peptides 21: 1007-1021.
124. Li L, Dong L, Wang S, (2013). Expression of the nociceptin/orphanin FQ receptor in the intestinal mucosa of IBS patients. Exp Ther Med 6: 679-683.
125. Liebel JT, Swandulla D, Zeilhofer HU, (1997). Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurones of the neonatal rat spinal cord. Br J Pharmacol 121: 425-432.
126. Lin AP, Ko MC, (2013). The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci 4: 214-224.
127. Linz K, Christoph T, Schiene K, Koch T, Englberger W, (2013). GRT-TA2210, a selective NOP receptor agonist, is active in mouse models of inflammatory and neuropathic pain. In: EFIC-8th 'Pain in Europe' Congress; 9-12 October 2013; Florence, Italy. 2013. p. Abs 599.
128. Liu EH, Nishiuchi Y, Kimura T, Tachibana S, (2006). Supraspinal nocistatin and its amide derivative antagonize the hyperalgesic effects of nociceptin in mice. Neurosci Lett 397: 59-63.
129. Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, et-al. (2012). Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A. J Nucl Med 53: 385-392.
130. Lou LG, Ma L, Pei G, (1997). Nociceptin/orphanin FQ activates protein kinase C, and this effect is mediated through phospholipase C/Ca2+ pathway. Biochem Biophys Res Commun 240: 304-308.
131. Lu N, Han M, Yang ZL, Wang YQ, Wu GC, Zhang YQ, (2010). Nociceptin/orphanin FQ in PAG modulates the release of amino acids, serotonin and norepinephrine in the rostral ventromedial medulla and spinal cord in rats. Pain 148: 414-425.
132. Lu SX, Higgins GA, Hodgson RA, Hyde LA, Del Vecchio RA, Guthrie DH, et-al. (2011). The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1] octane-3-carboxami de (SCH 655842): comparison of efficacy and side effects across rodent species. Eur J Pharmacol 661: 63-71.
133. Luo C, Kumamoto E, Furue H, Yoshimura M, (2001). Nociceptin-induced outward current in substantia gelatinosa neurones of the adult rat spinal cord. Neuroscience 108: 323-330.
134. Luo C, Kumamoto E, Furue H, Chen J, Yoshimura M, (2002). Nociceptin inhibits excitatory but not inhibitory transmission to substantia gelatinosa neurones of adult rat spinal cord. Neuroscience 109: 349-358.
135. Ma F, Xie H, Dong ZQ, Wang YQ, Wu GC, (2005). Expression of ORL1 mRNA in some brain nuclei in neuropathic pain rats. Brain Res 1043: 214-217.
136. Ma L, Cheng ZJ, Fan GH, Cai YC, Jiang LZ, Pei G, (1997). Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma x glioma NG108-15 hybrid cells. FEBS Lett 403: 91-94.
137. Maekawa K, Minami M, Masuda T, Satoh M, (1996). Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats. Pain 64: 365-371.
138. Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et-al. (2011). Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A 108: 19778-19783.
139. Malinowska B, Godlewski G, Schlicker E, (2002). Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system. J Physiol Pharmacol 53: 301-324.
140. Mandyam CD, Thakker DR, Standifer KM, (2003). Mu-opioid-induced desensitization of opioid receptor-like 1 and mu-opioid receptors: differential intracellular signaling determines receptor sensitivity. J Pharmacol Exp Ther 306: 965-972.
141. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et-al. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485: 321-326.
142. Mao J, (2012). Current challenges in translational pain research. Trends Pharmacol Sci 33: 568-573.
143. Margas W, Sedeek K, Ruiz-Velasco V, (2008). Coupling specificity of NOP opioid receptors to pertussis-toxin-sensitive G alpha proteins in adult rat stellate ganglion neurons using small interference RNA. J Neurophysiol 100: 1420-1432.
144. McDougall JJ, Pawlak M, Hanesch U, Schmidt RF, (2000). Peripheral modulation of rat knee joint afferent mechanosensitivity by nociceptin/orphanin FQ. Neurosci Lett 288: 123-126.
145. Meis S, Pape HC, (1998). Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J Neurosci 18: 8133-8144.
146. Menzies JR, Glen T, Davies MR, Paterson SJ, Corbett AD, (1999). In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13) NH(2) in the mouse and rat colon and the mouse vas deferens. Eur J Pharmacol 385: 217-223.
147. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et-al. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377: 532-535.
148. Mika J, Li Y, Weihe E, Schafer MK, (2003). Relationship of pronociceptin/orphanin FQ and the nociceptin receptor ORL1 with substance P and calcitonin gene-related peptide expression in dorsal root ganglion of the rat. Neurosci Lett 348: 190-194.
149. Mogil JS, Pasternak GW, (2001). The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53: 381-415.
150. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, Grandy DK, (1996a). Orphanin FQ is a functional anti-opioid peptide. Neuroscience 75: 333-337.
151. Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK, (1996b). Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 214: 131-134.
152. Mollereau C, Mouledous L, (2000). Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21: 907-917.
153. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et-al. (1994). ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341: 33-38.
154. Mollereau C, Simons MJ, Soularue P, Liners F, Vassart G, Meunier JC, et-al. (1996). Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci U S A 93: 8666-8670.
155. Monteillet-Agius G, Fein J, Anton B, Evans CJ, (1998). ORL-1 and mu opioid receptor antisera label different fibers in areas involved in pain processing. J Comp Neurol 399: 373-383.
156. Moran TD, Abdulla FA, Smith PA, (2000). Cellular neurophysiological actions of nociceptin/orphanin FQ. Peptides 21: 969-976.
157. Morgan MM, Grisel JE, Robbins CS, Grandy DK, (1997). Antinociception mediated by the periaqueductal gray is attenuated by orphanin FQ. Neuroreport 8: 3431-3434.
158. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et-al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today 17: 419-424.
159. Murali SS, Napier IA, Rycroft BK, Christie MJ, (2012). Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels. J Physiol 590: 1655-1667.
160. Nazzaro C, Rizzi A, Salvadori S, Guerrini R, Regoli D, Zeilhofer HU, et-al. (2007). UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides 28: 663-669.
161. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, et-al. (1999a). Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412: 563-605.
162. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson SJ Jr, (1999b). Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 406: 503-547.
163. Neal CR Jr, Akil H, Watson SJ Jr, (2001). Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain. J Chem Neuroanat 22: 219-249.
164. Neal CR Jr, Owens CE, Taylor LP, Hoversten MT, Akil H, Watson SJ Jr, (2003). Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat 25: 233-247.
165. Neal MJ, Cunningham JR, Paterson SJ, McKnight AT, (1997). Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurones. Br J Pharmacol 120: 1399-1400.
166. Neugebauer V, Li W, Bird GC, Han JS, (2004). The amygdala and persistent pain. Neuroscientist 10: 221-234.
167. + evoked glutamate release from rat cerebrocortical slices. Br J Pharmacol 119: 1081-1083.
168. Nicol B, Lambert DG, Rowbotham DJ, Okuda-Ashitaka E, Ito S, Smart D, et-al. (1998). Nocistatin reverses nociceptin inhibition of glutamate release from rat brain slices. Eur J Pharmacol 356: R1-R3.
169. Nicol B, Rowbotham DJ, Lambert DG, (2002). Nociceptin/orphanin FQ inhibits glutamate release from rat cerebellar and brain stem slices. Neurosci Lett 326: 85-88.
170. Nishi M, Takeshima H, Mori M, Nakagawara K, Takeuchi T, (1994). Structure and chromosomal mapping of genes for the mouse kappa-opioid receptor and an opioid receptor homologue (MOR-C). Biochem Biophys Res Commun 205: 1353-1357.
171. Nozaki-Taguchi N, Yamamoto T, (2005). Spinal opioid receptor like1 receptor agonist, but not N-methyl-D-aspartic acid antagonist, reverses the secondary mechanical allodynia induced by intradermal injection of capsaicin in rats. Anesth Analg 100: 1087-1092.
172. Obara I, Przewlocki R, Przewlocka B, (2005). Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 116: 17-25.
173. Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y, Kimura T, et-al. (1998). Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392: 286-289.
174. Okuda-Ashitaka E, Minami T, Tsubouchi S, Kiyonari H, Iwamatsu A, Noda T, et-al. (2012). Identification of NIPSNAP1 as a nocistatin-interacting protein involving pain transmission. J Biol Chem 287: 10403-10413.
175. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F, (1995). Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 199: 83-86.
176. Pan YX, Xu J, Wan BL, Zuckerman A, Pasternak GW, (1998). Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain. FEBS Lett 435: 65-68.
177. Pan YX, Bolan E, Pasternak GW, (2002). Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype. Biochem Biophys Res Commun 297: 659-663.
178. Pan Z, Hirakawa N, Fields HL, (2000). A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron 26: 515-522.
179. Peluso J, LaForge KS, Matthes HW, Kreek MJ, Kieffer BL, Gaveriaux-Ruff C, (1998). Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 81: 184-192.
180. Peluso J, Gaveriaux-Ruff C, Matthes HW, Filliol D, Kieffer BL, (2001). Orphanin FQ/nociceptin binds to functionally coupled ORL1 receptors on human immune cell lines and alters peripheral blood mononuclear cell proliferation. Brain Res Bull 54: 655-660.
181. Pettersson LM, Sundler F, Danielsen N, (2002). Expression of orphanin FQ/nociceptin and its receptor in rat peripheral ganglia and spinal cord. Brain Res 945: 266-275.
182. Pierce KL, Lefkowitz RJ, (2001). Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2: 727-733.
183. Podlesnik CA, Ko MC, Winger G, Wichmann J, Prinssen EP, Woods JH, (2011). The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl) 213: 53-60.
184. Pomonis JD, Billington CJ, Levine AS, (1996). Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport 8: 369-371.
185. Porreca F, Tang QB, Bian D, Riedl M, Elde R, Lai J, (1998). Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res 795: 197-203.
186. Raingo J, Castiglioni AJ, Lipscombe D, (2007). Alternative splicing controls G protein-dependent inhibition of N-type calcium channels in nociceptors. Nat Neurosci 10: 285-292.
187. Rashid MH, Inoue M, Toda K, Ueda H, (2004). Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther 309: 380-387.
188. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et-al. (1995). Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270: 792-794.
189. Reiss D, Wichmann J, Tekeshima H, Kieffer BL, Ouagazzal AM, (2008). Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. Eur J Pharmacol 579: 141-148.
190. Rice AS, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, et-al. (2008). Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139: 243-247.
191. Rizzi A, Nazzaro C, Marzola GG, Zucchini S, Trapella C, Guerrini R, et-al. (2006). Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 124: 100-108.
192. Rizzi A, Molinari S, Marti M, Marzola G, Calo' G, (2011). Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. Neuropharmacology 60: 572-579.
193. Roberto M, Siggins GR, (2006). Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala. Proc Natl Acad Sci U S A 103: 9715-9720.
194. Rosen A, Lundeberg T, Bytner B, Nylander I, (2000). Central changes in nociceptin dynorphin B and Met-enkephalin-Arg-Phe in different models of nociception. Brain Res 857: 212-218.
195. Rosenblum A, Marsch LA, Joseph H, Portenoy RK, (2008). Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 16: 405-416.
196. Rossi GC, Mathis JP, Pasternak GW, (1998). Analgesic activity of orphanin FQ2, murine prepro-orphanin FQ141-157 in mice. Neuroreport 9: 1165-1168.
197. Rossi GC, Pellegrino M, Shane R, Abbadie CA, Dustman J, Jimenez C, et-al. (2002). Characterization of rat prepro-orphanin FQ/nociceptin(-(154-181)-): nociceptive processing in supraspinal sites. J Pharmacol Exp Ther 300: 257-264.
198. Rutten K, De Vry J, Bruckmann W, Tzschentke TM, (2010). Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur J Pharmacol 645: 119-126.
199. Rutten K, De Vry J, Bruckmann W, Tzschentke TM, (2011). Pharmacological blockade or genetic knockout of the NOP receptor potentiates the rewarding effect of morphine in rats. Drug Alcohol Depend 114: 253-256.
200. Sakurada T, Katsuyama S, Sakurada S, Inoue M, Tan-No K, Kisara K, et-al. (1999). Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors. Br J Pharmacol 127: 1712-1718.
201. Sakurada T, Komatsu T, Moriyama T, Sasaki M, Sanai K, Orito T, et-al. (2005). Effects of intraplantar injections of nociceptin and its N-terminal fragments on nociceptive and desensitized responses induced by capsaicin in mice. Peptides 26: 2505-2512.
202. Sandin J, Georgieva J, Schott PA, Ogren SO, Terenius L, (1997). Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 9: 194-197.
203. Schiene K, Christoph T, Kögel B, Tzschentke TM, (2013). Antinociceptive, antihyperalgesic and antiallodynic activity of the NOP receptor agonist Ro65-6570 in rodent models of pain. In: EFIC-8th 'Pain in Europe' Congress; 9-12 October 2013; Florence, Italy. 2013. p. Abs 606.
204. Schlicker E, Morari M, (2000). Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 21: 1023-1029.
205. Schulz S, Schreff M, Nuss D, Gramsch C, Hollt V, (1996). Nociceptin/orphanin FQ and opioid peptides show overlapping distribution but not co-localization in pain-modulatory brain regions. Neuroreport 7: 3021-3025.
206. Scoto GM, Arico G, Iemolo A, Ronsisvalle S, Parenti C, (2009). Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain. Life Sci 85: 206-210.
207. Serhan CN, Fierro IM, Chiang N, Pouliot M, (2001). Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J Immunol 166: 3650-3654.
208. Serrano-Gomez A, Thompson JP, Lambert DG, (2011). Nociceptin/orphanin FQ in inflammation and sepsis. Br J Anaesth 106: 6-12.
209. Shane R, Lazar DA, Rossi GC, Pasternak GW, Bodnar RJ, (2001). Analgesia elicited by OFQ/nociceptin and its fragments from the amygdala in rats. Brain Res 907: 109-116.
210. Shane R, Acosta J, Rossi GC, Bodnar RJ, (2003). Reciprocal interactions between the amygdala and ventrolateral periaqueductal gray in mediating of Q/N(1-17)-induced analgesia in the rat. Brain Res 980: 57-70.
211. Shenoy SK, Lefkowitz RJ, (2011). beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32: 521-533.
212. Shu YS, Zhao ZQ, Li MY, Zhou GM, (1998). Orphanin FQ/nociceptin modulates glutamate- and kainic acid-induced currents in acutely isolated rat spinal dorsal horn neurons. Neuropeptides 32: 567-571.
213. Sikandar S, Ronga I, Iannetti GD, Dickenson AH, (2013). Neural coding of nociceptive stimuli-from rat spinal neurones to human perception. Pain 154: 1263-1273.
214. Singh SR, Sullo N, D'Agostino B, Brightling CE, Lambert DG, (2013). The effects of nociceptin peptide (N/OFQ)-receptor (NOP) system activation in the airways. Peptides 39: 36-46.
215. Sobczak M, Salaga M, Storr M, Fichna J, (2013). Nociceptin/orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases. Curr Drug Targets 14: 1203-1209.
216. Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Salaga M, Storr M, et-al. (2014). Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases. J Pharmacol Exp Ther 348: 401-409.
217. Sotgiu ML, Bellomi P, Biella GE, (2004). Efficacy of nociceptin inhibition on WDR neuron activity is enhanced in mononeuropathic rats. Brain Res 998: 251-254.
218. Spampinato S, Di TR, Qasem AR, (2001). Nociceptin-induced internalization of the ORL1 receptor in human neuroblastoma cells. Neuroreport 12: 3159-3163.
219. Spampinato S, Di TR, Alessandri M, Murari G, (2002). Agonist-induced internalization and desensitization of the human nociceptin receptor expressed in CHO cells. Cell Mol Life Sci 59: 2172-2183.
220. Spampinato S, Baiula M, Calienni M, (2007). Agonist-regulated internalization and desensitization of the human nociceptin receptor expressed in CHO cells. Curr Drug Targets 8: 137-146.
221. Stanfa LC, Chapman V, Kerr N, Dickenson AH, (1996). Inhibitory action of nociceptin on spinal dorsal horn neurones of the rat, in vivo. Br J Pharmacol 118: 1875-1877.
222. Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC, (2013). Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/mu-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther 346: 11-22.
223. Sukhtankar DD, Lee H, Rice KC, Ko MC, (2014). Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology (Berl) 231: 1377-1387.
224. Sun RQ, Wang Y, Zhao CS, Chang JK, Han JS, (2001). Changes in brain content of nociceptin/orphanin FQ and endomorphin 2 in a rat model of neuropathic pain. Neurosci Lett 311: 13-16.
225. Sun YY, Luo C, Li Z, Chen J, (2004). Differential actions of intrathecal nociceptin on persistent spontaneous nociception, hyperalgesia and inflammation produced by subcutaneous bee venom injection in conscious rats. Sheng Li Xue Bao 56: 321-327.
226. Suzukawa M, Matsumoto M, Collins JG, Kitahata LM, Yuge O, (1983). Dose-response suppression of noxiously evoked activity of WDR neurons by spinally administered fentanyl. Anesthesiology 58: 510-513.
227. Takita K, Morimoto Y, (2008). Nociceptin/orphanin FQ causes non-quantal slowing of respiratory rhythm in brainstem-spinal cord preparation from newborn rat. Neurosci Lett 443: 129-133.
228. Takita K, Morimoto Y, Kemmotsu O, (2003). Roles of nociceptin/orphanin FQ and nociceptin/orphanin FQ peptide receptor in respiratory rhythm generation in the medulla oblongata: an in vitro study. Br J Anaesth 91: 385-389.
229. Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, et-al. (2012). Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485: 395-399.
230. Thompson JP, Serrano-Gomez A, McDonald J, Ladak N, Bowrey S, Lambert DG, (2013). The nociceptin/orphanin FQ system is modulated in patients admitted to ICU with sepsis and after cardiopulmonary bypass. PLoS ONE 8: e76682.
231. Tian JH, Xu W, Fang Y, Mogil JS, Grisel JE, Grandy DK, et-al. (1997a). Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol 120: 676-680.
232. Tian JH, Xu W, Zhang W, Fang Y, Grisel JE, Mogil JS, et-al. (1997b). Involvement of endogenous orphanin FQ in electroacupuncture-induced analgesia. Neuroreport 8: 497-500.
233. Toll L, (2013). The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders. Curr Pharm Des 19: 7451-7460.
234. Toll L, Khroyan TV, Polgar WE, Jiang F, Olsen C, Zaveri NT, (2009). Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. J Pharmacol Exp Ther 331: 954-964.
235. Uchiyama H, Toda A, Hiranita T, Watanabe S, Eyanagi R, (2008). Role of amygdaloid nuclei in the anxiolytic-like effect of nociceptin/orphanin FQ in rats. Neurosci Lett 431: 66-70.
236. Urch CE, Donovan-Rodriguez T, Gordon-Williams R, Bee LA, Dickenson AH, (2005). Efficacy of chronic morphine in a rat model of cancer-induced bone pain: behavior and in dorsal horn pathophysiology. J Pain 6: 837-845.
237. Varty GB, Hyde LA, Hodgson RA, Lu SX, McCool MF, Kazdoba TM, et-al. (2005). Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 182: 132-143.
238. Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, et-al. (2008). The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8- azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther 326: 672-682.
239. Vaughan CW, Ingram SL, Christie MJ, (1997). Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 17: 996-1003.
240. Vaughan CW, Connor M, Jennings EA, Marinelli S, Allen RG, Christie MJ, (2001). Actions of nociceptin/orphanin FQ and other prepronociceptin products on rat rostral ventromedial medulla neurons in vitro. J Physiol 534: 849-859.
241. Vitale G, Arletti R, Ruggieri V, Cifani C, Massi M, (2006). Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats. Peptides 27: 2193-2200.
242. Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, et-al. (2005). Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J Neurochem 92: 1285-1294.
243. Wang JB, Johnson PS, Imai Y, Persico AM, Ozenberger BA, Eppler CM, et-al. (1994). cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 348: 75-79.
244. Wang JL, Zhu CB, Cao XD, Wu GC, (1999a). Distinct effect of intracerebroventricular and intrathecal injections of nociceptin/orphanin FQ in the rat formalin test. Regul Pept 79: 159-163.
245. Wang T, Li SR, Dai X, Peng YL, Chen Q, Wang R, (2006). Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice. Brain Res 1085: 43-48.
246. Wang XM, Zhang KM, Mokha SS, (1996). Nociceptin (orphanin FQ), an endogenous ligand for the QRL1 (opioid-receptor-like1) receptor; modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli. J Neurophysiol 76: 3568-3572.
247. Wang YQ, Zhu CB, Cao XD, Wu GC, (1999b). Supraspinal hyperalgesia and spinal analgesia by [Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 in rat. Eur J Pharmacol 376: R1-R3.
248. Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH, (1995). Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Brain Res Mol Brain Res 32: 342-347.
249. Wiech K, Tracey I, (2009). The influence of negative emotions on pain: behavioral effects and neural mechanisms. Neuroimage 47: 987-994.
250. Witta J, Palkovits M, Rosenberger J, Cox BM, (2004). Distribution of nociceptin/orphanin FQ in adult human brain. Brain Res 997: 24-29.
251. Wu EH, Lo RK, Wong YH, (2003). Regulation of STAT3 activity by G16-coupled receptors. Biochem Biophys Res Commun 303: 920-925.
252. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, et-al. (2012). Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485: 327-332.
253. Xie G, Ito E, Maruyama K, Pietruck C, Sharma M, Yu L, et-al. (2000). An alternatively spliced transcript of the rat nociceptin receptor ORL1 gene encodes a truncated receptor. Brain Res Mol Brain Res 77: 1-9.
254. Xie GX, Meuser T, Pietruck C, Sharma M, Palmer PP, (1999). Presence of opioid receptor-like (ORL1) receptor mRNA splice variants in peripheral sensory and sympathetic neuronal ganglia. Life Sci 64: 2029-2037.
255. Xu IS, Grass S, Wiesenfeld-Hallin Z, Xu XJ, (1999). Effects of intrathecal orphanin FQ on a flexor reflex in the rat after inflammation or peripheral nerve section. Eur J Pharmacol 370: 17-22.
256. Xu XJ, Hao JX, Wiesenfeld-Hallin Z, (1996). Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 7: 2092-2094.
257. Yamamoto T, Nozaki-Taguchi N, (1997). Effects of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, and N-methyl-D-aspartate receptor antagonists on the thermal hyperalgesia induced by partial sciatic nerve injury in the rat. Anesthesiology 87: 1145-1152.
258. Yamamoto T, Nozaki-Taguchi N, Kimura S, (1997a). Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, in the rat formalin test. Neuroscience 81: 249-254.
259. Yamamoto T, Nozaki-Taguchi N, Kimura S, (1997b). Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by carageenan injection into the rat paw. Brain Res 754: 329-332.
260. Yamamoto T, Nozaki-Taguchi N, Kimura S, (1997c). Effects of intrathecally administered nociceptin, an opioid receptor-like1 (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci Lett 224: 107-110.
261. Yamamoto T, Ohtori S, Chiba T, (2000). Effects of pre-emptively administered nociceptin on the development of thermal hyperalgesia induced by two models of experimental mononeuropathy in the rat. Brain Res 871: 192-200.
262. Yu LC, Lu JT, Huang YH, Meuser T, Pietruck C, Gabriel A, et-al. (2002). Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats. Brain Res 945: 88-96.
263. Zeilhofer HU, Calo G, (2003). Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy? J Pharmacol Exp Ther 306: 423-429.
264. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL, (1999). p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 162: 3819-3829.
265. Zhang NR, Planer W, Siuda ER, Zhao HC, Stickler L, Chang SD, et-al. (2012). Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR) desensitization, internalization, and arrestin signaling. J Biol Chem 287: 42019-42030.
266. Zhao CS, Li BS, Zhao GY, Liu HX, Luo F, Wang Y, et-al. (1999). Nocistatin reverses the effect of orphanin FQ/nociceptin in antagonizing morphine analgesia. Neuroreport 10: 297-299.
267. Zhu CB, Cao XD, Xu SF, Wu GC, (1997). Orphanin FQ potentiates formalin-induced pain behavior and antagonizes morphine analgesia in rats. Neurosci Lett 235: 37-40.
268. Zollner C, Stein C, (2007). Opioids. Handb Exp Pharmacol 177: 31-63.